Study of ALN-CIDEB for adults with liver scarring from MASH
Part of Digestive system clinical trials.
This study tests an investigational drug called ALN-CIDEB for people with MASH, a liver condition linked to metabolic issues, that has caused moderate liver scarring. The goal is to see if the drug can reduce liver damage and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of MASH or signs of it based on tests and metabolic risk factors.
- A recent liver biopsy shows a certain level of liver damage (NAS score of 4 or more) and moderate scarring (stage F2 or F3).
- A special liver scan (FibroScan) shows a score above 0.35, indicating significant liver stiffness.
- You do not have other chronic liver diseases or a history of drug-induced liver injury in the past year.
- You have not had a liver transplant, are not on a transplant list, and your liver function score (MELD) is 12 or less.
- You have not had alcohol or substance abuse in the past year, and you are not currently using GLP-1 medications for MASH unless on a stable dose for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
This study tests an investigational medicine called pemvidutide to see if it can reduce liver scarring in people with MASH (a liver condition linked to excess weight and metabolic issues). It may help improve liver health and potentially slow or reverse the condition.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests an experimental drug for people with a type of fatty liver disease called MASH that has led to liver scarring. The goal is to see if the drug can help reduce liver damage and improve liver health.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.